I -year survival rate and an estimated 62% 18-month survival rate. One-year survival was 74% in patients without prior Yervoy treatment and 65% in Yerboy-experienced patients. This data appears at least as strong as and potentially stronger than nivo's monotherapy data, although we see a promising ro